We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+6.39%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$779M
AUM Growth
-$45.9M
Cap. Flow
-$5.82M
Cap. Flow %
-0.75%
Top 10 Hldgs %
71.03%
Holding
35
New
6
Increased
2
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
2
TVTX icon
Travere Therapeutics
TVTX
+$31.8M
3
NUVL
Nuvalent
NUVL
+$23.3M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$10.1M
5
ATYR
aTyr Pharma
ATYR
+$9.36M

Top Sells

Rank Stock Value
1
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$24.5M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$19.4M
3
EPIX
ESSA Pharma
EPIX
+$17.9M
4
RAPT
RAPT Therapeutics
RAPT
+$12.4M
5
KURA icon
Kura Oncology
KURA
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 96.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRDN icon
26
Viridian Therapeutics
VRDN
$2.09B
$321K 0.04%
19,495
– –
ACET icon
27
Adicet Bio
ACET
$85.2M
– –
-11,481
Closed -$1.89M
ALGS icon
28
Aligos Therapeutics
ALGS
$26.2M
– –
-16,335
Closed -$8.32M
EPIX
29
DELISTED
ESSA Pharma
EPIX
– –
-625,754
Closed -$17.9M
KROS icon
30
Keros Therapeutics
KROS
$199M
– –
-272,306
Closed -$11.6M
KURA icon
31
Kura Oncology
KURA
$800M
– –
-575,000
Closed -$12M
RAPT
32
DELISTED
RAPT Therapeutics
RAPT
– –
-48,875
Closed -$12.4M
HARP
33
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-51,201
Closed -$7.1M
PRVB
34
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-2,902,744
Closed -$24.5M
TRIL
35
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-2,001,686
Closed -$19.4M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2021 Portfolio in Review

As of Q3 2021, VR Adviser held 35 positions worth $779M, down 5.6% from $824M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

VR Adviser's Q3 2021 filing shows 6 new, 2 increased, 6 reduced and 9 closed positions. Its largest new stake was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M. The largest sale was Provention Bio, Inc. Common Stock, an estimated $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier.

  • VR Adviser's largest Q3 2021 buy was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M.
  • VR Adviser added most to GH Research in Q3 2021, an estimated $7.46M increase.
  • VR Adviser's biggest Q3 2021 reduction was Cullinan Oncology, cutting an estimated $7.22M.
  • VR Adviser fully exited Provention Bio, Inc. Common Stock in Q3 2021, selling an estimated $24.5M.
  • VR Adviser's ten largest holdings make up 71% of its $779M portfolio in Q3 2021.
  • VR Adviser opened 6 new positions and closed 9 in Q3 2021.
  • VR Adviser's portfolio value fell 5.6% quarter-over-quarter to $779M.

Based on VR Adviser's 13F filing for Q3 2021, filed 15 Nov 2021.